Table 3.
Correlation between clinicopathologic features and expression of mRNA CCND1 isoforms and cyclin D1b protein in 125 patients with classic variant of papillary thyroid carcinoma.
| Characteristic | n | High Expression of CCND1 mRNA Isoforms | High Expression of Cyclin D1b Protein | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CCND1a | p-Value | CCND1b | p-Value | Nuclear | p-Value | Cytoplasmic | p-Value | ||
| Age (years) | 0.022 | 0.438 | 0.289 | 0.358 | |||||
| <55 | 94 | 30 (31.9%) | 44 (46.8%) | 60 (63.8%) | 68 (72.3%) | ||||
| ≥55 | 31 | 17 (54.8%) | 17 (54.8%) | 23 (74.2%) | 25 (80.6%) | ||||
| Gender | 0.499 | 0.885 | 0.122 | 0.040 | |||||
| Female | 97 | 38 (39.2%) | 47 (48.5%) | 61 (62.9%) | 68 (70.1%) | ||||
| Male | 28 | 9 (32.1%) | 14 (50.0%) | 22 (78.6%) | 25 (89.3%) | ||||
| Primary tumor size (cm) | 0.709 | 0.078 | 0.473 | 0.156 | |||||
| ≤1.0 | 80 | 28 (35.0%) | 33 (41.3%) | 51 (63.8%) | 56 (70.0%) | ||||
| 1.0–2.0 | 30 | 13 (43.3%) | 19 (63.3%) | 20 (66.7%) | 23 (76.7%) | ||||
| >2.0 | 15 | 6 (40.0%) | 9 (60.0%) | 12 (80.0%) | 14 (93.3%) | ||||
| Extrathyroidal extension | 0.206 | 0.084 | 0.823 | 0.411 | |||||
| Absent | 59 | 19 (32.2%) | 24 (40.7%) | 38 (64.4%) | 41 (69.5%) | ||||
| Microscopic | 58 | 24 (41.4%) | 32 (55.2%) | 39 (67.2%) | 45 (77.6%) | ||||
| Gross | 8 | 4 (50.0%) | 5 (62.5%) | 6 (75.0%) | 7 (87.5%) | ||||
| Lymph node metastasis | 0.661 | 0.038 | 0.006 | 0.005 | |||||
| Absent | 59 | 21 (35.6%) | 23 (39.0%) | 32 (54.2%) | 37 (62.7%) | ||||
| Present | 66 | 26 (39.4%) | 38 (57.6%) | 51 (77.3%) | 56 (84.8%) | ||||
| Lateral lymph node metastasis | 0.142 | 0.144 | 0.202 | 0.065 | |||||
| Absent | 99 | 34 (34.3%) | 45 (45.5%) | 63 (63.6%) | 70 (70.7%) | ||||
| Present | 26 | 13 (50.0%) | 16 (61.5%) | 20 (76.9%) | 23 (88.5%) | ||||
| Distant metastasis | 0.007 | 0.059 | 0.167 | 0.327 | |||||
| Absent | 120 | 42 (35.0%) | 81 (49.1%) | 78 (65.0%) | 88 (73.3%) | ||||
| Present | 5 | 5 (100%) | 5 (100%) | 5 (100%) | 5 (100%) | ||||
| BRAF V600E mutation | 0.743 | 0.713 | 0.694 | 0.234 | |||||
| Negative | 17 | 7 (41.2%) | 9 (52.9%) | 12 (70.6%) | 15 (88.2%) | ||||
| Positive | 108 | 40 (37.0%) | 52 (48.1%) | 71 (65.7%) | 78 (72.2%) | ||||
| Recurrence risk | 0.258 | 0.056 | 0.190 | 0.111 | |||||
| Low | 48 | 14 (29.2%) | 17 (35.4%) | 30 (62.5%) | 33 (68.8%) | ||||
| Intermediate | 54 | 22 (40.7%) | 30 (55.6%) | 34 (63.0%) | 39 (72.2%) | ||||
| High | 23 | 11 (47.8%) | 14 (60.9%) | 19 (82.6%) | 21 (91.3%) | ||||
| AJCC stage, 7th edition | 0.014 | 0.007 | 0.065 | 0.025 | |||||
| I | 70 | 20 (28.6%) | 27 (38.6%) | 42 (60.0%) | 47 (67.1%) | ||||
| II | 3 | 2 (66.7%) | 2 (66.7%) | 2 (66.7%) | 2 (66.7%) | ||||
| III | 47 | 22 (44.9%) | 29 (59.2%) | 36 (73.5%) | 41 (83.7%) | ||||
| IV | 3 | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | ||||
| AJCC stage, 8th edition | 0.004 | 0.008 | 0.038 | 0.131 | |||||
| I | 107 | 35 (32.7%) | 47 (43.9%) | 67 (62.6%) | 77 (72.0%) | ||||
| II | 16 | 10 (62.5%) | 12 (75.0%) | 14 (87.5%) | 14 (87.5%) | ||||
| IV | 2 | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | ||||